摘要
心血管疾病是全球首要死亡原因,动脉粥样硬化是其潜在病理机制。目前,动脉粥样硬化的炎症理论已深入人心。Canakinumab Anti-Inflammatory Thrombosis Outcome Study(CANTOS)直接验证这一理论,它证明了白介素(IL)-1β的特异性抗体canakinumab 的临床治疗前景。IL-1β是IL-1 家族中经典的促炎细胞因子,可促进动脉粥样硬化形成及斑块不稳定。炎症小体参与炎症的发生与进展,NLRP3 炎症小体是研究最为广泛的炎症小体,激活的NLRP3 炎症小体可促进IL-1β的分泌与成熟,导致动脉粥样硬化进展。现主要综述NLPR3/IL-1β途径在动脉粥样硬化中的作用,并结合CANTOS 结果探讨抗炎治疗在临床上的应用前景。
Cardiovascular disease is currently the leading cause of death worldwide, and atherosclerosis (AS) is the potential pathologic mechanism. At present, the theory of inflammation of atherosclerosis has been deeply comfirmed. The Canakinumab Anti- Inflammatory Thrombosis Outcome Study(CANTOS) results directly validate this theory, which demonstrates the clinical therapeutic potential of IL-1β specific antibody canakinumab. IL-1β is a classical pro-inflammatory cytokine in the IL-1 family that promotes AS and plaque instability. Inflammasomes are involved in the development and progression of inflammation. NLRP3 inflammasome was the most widely studied. Activated NLRP3 inflammasome promote the secretion and maturation of IL-1β, leading to the progression of AS. This article mainly describes the role of NLPR3/IL-1β pathway in AS, and combined with the results of CANTOS to explore the clinical application of anti-inflammatory therapy.
作者
武亚琳
梁斌
杨志明
WU Yalin;LIANG Bin;YANG Zhiming(Shanxi Medical University, Taiyuan 030000, Shanxi, China;Department of Cardiology, The Second Clinical Medical College, Shanxi Medical University, Taiyuan 030000, Shanxi, China)
出处
《心血管病学进展》
CAS
2019年第6期943-946,共4页
Advances in Cardiovascular Diseases
基金
国家自然科学基金面上项目(81570273)
